JPRN-UMIN000023464RecruitingPhase 2
A randomized phaseII study to evaluate quality of life after total gastrectomy using a linear stapler vs a circular stapler for esophagojejunostomy - Laparoscopic esophagojejunostomy with linear or circular stapler
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Shizuoka Cancer Center
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1. Other active cancer 2. Active infectious disease 3. Possibly pregnant, or breast feeding woman 4. Psychiatric disorder 5. Receiving steroids 6. Acute myocardial infarction within 6 months or unstable angina 7. Uncontrolled hypertension 8. Uncontrolled diabetes mellitus and receiving insulin treatment 9. Pulmonary disease requiring continuous oxygen therapy
Investigators
Similar Trials
Recruiting
Phase 2
A randomized phase II study to evaluate quality of life after total gastrectomy using a linear stapler vs a circular stapler for esophagojejunostomyGastric cancerJPRN-jRCT1042180138Terashima Masanori50
Completed
Phase 2
A randomized phase II study for the evaluation of T cell depleted non-myeloablative allogeneic stem cell transplantation followed by early consolidation with lenalidomide or lenalidomide combined with bortezomib and subsequent DLI for patients with multiple myeloma in progression or relapse following first line therapyKahlers disease10035227Multiple MyelomaNL-OMON36688HOVO110
Active, not recruiting
Not Applicable
/ASubjects affected by non-segmental vitiligoMedDRA version: 14.1Level: PTClassification code 10062080Term: Pigmentation disorderSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2011-000169-10-ITCLINUVEL PHARMACUETICALS LTD.60
Active, not recruiting
Phase 1
ocally Advanced or Metastatic Hepatocellular Carcinoma (HCC): Evaluation of the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with BudigalimabHepatocellular CarcinomaCTIS2022-502948-13-00Abbvie Deutschland GmbH & Co. KG120
Active, not recruiting
Phase 1
A study to evaluate the switch from prednisone to dexamethasone in prostate cancer patients being treated with abirateroneEUCTR2021-000943-30-ESSOGUG (Spanish Genitourinary Oncologic Group)110